Trial · NCT03173781
Effects of Droxidopa When Measuring Gait Speed, Kyphosis, and Functional Reach in Parkinson's Disease
NCT03173781, Not applicable, Completed, Colorado Springs Neurological Associates
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effects of Droxidopa When Measuring Gait Speed, Kyphosis, and Functional Reach in Parkinson's Disease. Trials, record NCT03173781. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03173781
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effects of Droxidopa When Measuring Gait Speed, Kyphosis, and Functional Reach in Parkinson's Disease
- NCT number
- NCT03173781
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 21 participants, actual
- Lead sponsor
- Colorado Springs Neurological Associates
- Conditions
- Parkinson's Disease
- Interventions
- droxidopa, Placebo
- First posted
- 2017-06-02
- Last updated
- 2018-06-25
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Evaluate the efficacy of droxidopa when measuring walking speed using the 10 meter walk test . | 24 months | 10 meter walk test * Subject walks without assistance 10 meters (32.8 feet). * Assistive devices can be used but should be kept consistent and documented from test to test. * If physical assistance is required to walk, this should not be performed * Collect three trials and calculate the average of the three trials * Individuals are permitted to use the assistive device they typically use in the community, but without the assistance of another person. |
| Primary | Evaluate the efficacy of droxidopa when measuring walking speed using Dual Task Timed Up and Go test | 24 months | * Subjects are given verbal instructions to stand up from a chair, walk 3 meters as quickly and safely as possible, cross a line marked on the floor, turn around, walk back, and sit down. * In the TUG (Cognitive), individuals were asked to complete the test while counting backward by threes from a randomly selected number between 20 and 100. |
| Secondary | Evaluate the efficacy of droxidopa when measuring degree of thoracic curvature using the Flexicurve rule | 24 months | Flexi-curve measurement * Instruct subject to "stand in your usual best posture" * Identify C7 spinous process. * Identify the L-S interspace. * Mark each landmark (C7 process and L-S space) with a single horizontal grease pencil line. * Make sure the patient is standing in their usual best posture so that the marks are in the correct place during measurement using flexi-curve ruler. |
| Secondary | Evaluate the efficacy of droxidopa when measuring fall risk using the Forward Functional Reach test. | 24 months | Forward Functional Reach test * Using a yardstick mounted on the wall at shoulder height, ask the subject to position body close to, but not touching the wall with arm outstretched and hand fisted. Take note of the starting position by determining what number the MCP joints line up with on the rule. * Have the subject reach as far forward as possible in a plane parallel with the measuring device. * Instruct subject to "Reach as far forward as you can go without taking a step." Subjects are free to use various reaching strategies. * Take note of the end position of the MCP joints against the ruler, and record the difference between the starting and end position numbers. * If the feet move, that trial must be discarded and repeated. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03173781
GET https://conductscience.org/api/trials/v1/NCT03173781/registered